Antibiotic Treatment for Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)

First-Line Antibiotics for Hospitalized AECOPD

The American Thoracic Society recommends amoxicillin-clavulanate as the first-line agent for hospitalized AECOPD patients without Pseudomonas risk factors 1, 2
The European Respiratory Society suggests fluoroquinolones (levofloxacin 750 mg daily or moxifloxacin) as alternatives for hospitalized AECOPD patients without Pseudomonas risk factors 1, 2
The use of second-line antibiotics, including macrolides like azithromycin, demonstrated superior treatment success compared to older first-line agents, with an odds ratio of 0.51 1, 2
For patients with Pseudomonas risk factors, ciprofloxacin or levofloxacin (750 mg/24h or 500 mg twice daily) is recommended as the antibiotic of choice 1, 2

Azithromycin reduces exacerbation rates by 25-30% when used prophylactically (RR 0.73, 95% CI 0.58-0.91) in patients with moderate-to-severe COPD and recurrent exacerbations 3, 4
The landmark Albert trial demonstrated a reduction from 1.83 to 1.48 exacerbations per patient-year with azithromycin 250 mg daily 3, 4

The assessment of Pseudomonas risk factors, including severe airflow obstruction (FEV1 <30%), frequent antibiotic use, recent hospitalization, chronic oral corticosteroid use, and bronchiectasis, is crucial for selecting the appropriate antibiotic 5, 6, 2, 3
The choice of antibiotic should be based on risk stratification, with amoxicillin-clavulanate or fluoroquinolones recommended for patients without Pseudomonas risk factors, and ciprofloxacin or levofloxacin recommended for patients with Pseudomonas risk factors 1, 2

Mandatory pre-treatment assessment includes ECG to measure QTc interval, baseline liver function tests, hearing assessment, and sputum culture for baseline resistance patterns 6, 7, 3, 4, 8
The most concerning adverse effect is increased macrolide resistance, with 81% of newly colonized patients on azithromycin developing resistant organisms versus 41% on placebo 8

A 5-7 day course of levofloxacin (750 mg daily) is as effective as 10 days of β-lactams, and even 2-day courses have shown non-inferiority to 7-day courses, providing excellent efficacy against S. pneumoniae and common COPD pathogens, with 89-90% predicted clinical efficacy in AECOPD 9
The European Respiratory Society recommends completing a full course of levofloxacin before resuming azithromycin prophylaxis, with a strength of evidence supporting the use of a single antibiotic based on severity and risk factors 10

The American Thoracic Society and European Respiratory Society support the use of levofloxacin 750 mg once daily for 5-7 days in hospitalized patients, and 500 mg daily for outpatients, with the option to switch from IV to oral by day 3 if clinically stable 9
Azithromycin prophylaxis (250 mg daily) should be resumed after completing the levofloxacin course, as recommended by the European Respiratory Society, with evidence from the BACE trial demonstrating reduced treatment failure and step-up in hospital care 10